Roger von Moos

Summary

Country: Switzerland

Publications

  1. pmc Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
    Nicola L Schoenewolf
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Case Rep Oncol 5:280-9. 2012
  2. doi request reprint Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
    Roger von Moos
    Kantonsspital Graubunden, Loestrasse 170, 7000, Chur, Switzerland
    Support Care Cancer 21:3497-507. 2013
  3. ncbi request reprint Reducing the burden of bone metastases: current concepts and treatment options
    Roger von Moos
    Medical Oncology Haematology, Kantonsspital Graubunden, 7000, Chur, Switzerland
    Support Care Cancer 21:1773-83. 2013
  4. doi request reprint First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
    R von Moos
    Department of Medicine Oncology, Kantonal Hospital Graubuenden, Chur, Switzerland
    Ann Oncol 23:531-6. 2012
  5. doi request reprint Denosumab: first data and ongoing studies on the prevention of bone metastases
    Roger von Moos
    Department Medical Oncology, Kantonsspital Graubuenden, Chur, Switzerland
    Recent Results Cancer Res 192:187-96. 2012
  6. doi request reprint Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)
    Roger von Moos
    Kantonsspital Graubunden, Switzerland
    Onkologie 33:295-9. 2010
  7. doi request reprint Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes
    Roger von Moos
    Medizinische Klinik, Onkologie und Hämatologie, Chur, Switzerland
    Onkologie 33:447-50. 2010
  8. doi request reprint Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communication
    Roger von Moos
    Medical Oncology, Cantonal Hospital Graubuenden, 7000 Chur, Switzerland
    J Immunother 33:92-5. 2010
  9. doi request reprint Metastatic bone pain: treatment options with an emphasis on bisphosphonates
    Roger von Moos
    Medical Oncology, Kantonsspital Graubunden, Loestrasse 170, Chur, 7000, Switzerland
    Support Care Cancer 16:1105-15. 2008
  10. doi request reprint Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
    Richard Cathomas
    Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland
    Support Care Cancer 18:1263-70. 2010

Detail Information

Publications18

  1. pmc Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
    Nicola L Schoenewolf
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Case Rep Oncol 5:280-9. 2012
    ..Melanoma is characterized by a high frequency of BRAF mutations. It is unknown if the BRAF mutation status has any predictive value for therapeutic approaches such as angiogenesis inhibition...
  2. doi request reprint Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
    Roger von Moos
    Kantonsspital Graubunden, Loestrasse 170, 7000, Chur, Switzerland
    Support Care Cancer 21:3497-507. 2013
    ..This analysis evaluated patient-reported outcomes and analgesic use in patients with bone metastases from solid tumours across three comparative studies of denosumab and zoledronic acid...
  3. ncbi request reprint Reducing the burden of bone metastases: current concepts and treatment options
    Roger von Moos
    Medical Oncology Haematology, Kantonsspital Graubunden, 7000, Chur, Switzerland
    Support Care Cancer 21:1773-83. 2013
    ..This article reviews the personal, social and economic burdens of bone metastases and SREs, and approaches to treatment...
  4. doi request reprint First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
    R von Moos
    Department of Medicine Oncology, Kantonal Hospital Graubuenden, Chur, Switzerland
    Ann Oncol 23:531-6. 2012
    ..1 months. Bevacizumab has an inhibitory effect on the proliferation of melanoma and sprouting endothelial cells. We evaluated the addition of bevacizumab to temozolomide to improve efficacy in stage IV melanoma...
  5. doi request reprint Denosumab: first data and ongoing studies on the prevention of bone metastases
    Roger von Moos
    Department Medical Oncology, Kantonsspital Graubuenden, Chur, Switzerland
    Recent Results Cancer Res 192:187-96. 2012
    ..98]; P = 0.028). This is the first study to demonstrate the clinical benefit of a bone-targeted agent in this setting. Further evaluation of denosumab in the prevention of metastatic disease is warranted and ongoing in other tumor types...
  6. doi request reprint Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)
    Roger von Moos
    Kantonsspital Graubunden, Switzerland
    Onkologie 33:295-9. 2010
    ..A phase I multicentre trial was conducted to define the recommended dose of capecitabine in combination with oxaliplatin and irinotecan (OCX) in metastatic colorectal cancer...
  7. doi request reprint Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes
    Roger von Moos
    Medizinische Klinik, Onkologie und Hämatologie, Chur, Switzerland
    Onkologie 33:447-50. 2010
    ..This current study focuses on the renal safety of the extended use of ibandronate...
  8. doi request reprint Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communication
    Roger von Moos
    Medical Oncology, Cantonal Hospital Graubuenden, 7000 Chur, Switzerland
    J Immunother 33:92-5. 2010
    ..Thus, intralesional therapy with IFN-alpha2b may be a viable treatment option in patients with locally advanced melanoma who have progressed on prior radiotherapy, polychemotherapy, and/or multikinase antiangiogenic-based therapy...
  9. doi request reprint Metastatic bone pain: treatment options with an emphasis on bisphosphonates
    Roger von Moos
    Medical Oncology, Kantonsspital Graubunden, Loestrasse 170, Chur, 7000, Switzerland
    Support Care Cancer 16:1105-15. 2008
    ..Once metastatic cells are established within the bone matrix, skeletal integrity becomes increasingly compromised. Bone lesions lead to various complications, including bone pain, fractures and spinal cord compression...
  10. doi request reprint Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
    Richard Cathomas
    Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland
    Support Care Cancer 18:1263-70. 2010
    ..No preventive strategy has definitively been established. Because this neuropathy is triggered by cold, we hypothesized that infusing oxaliplatin at 37 degrees C might reduce neuropathy...
  11. doi request reprint Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
    Peter Schraml
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Oncol Rep 28:654-8. 2012
    ..The MGMT promoter methylation status may be a promising predictive marker for temozolomide therapy in metastatic melanoma patients. Larger sample sizes may help to validate significant differences in survival type endpoints...
  12. doi request reprint A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer
    Miklos Pless
    Medical Oncology, Kantonsspital Winterthur, Switzerland
    Lung Cancer 81:445-50. 2013
    ..Low intensity, intermediate frequency, alternating electric fields (Tumor Treating Fields; TTFields) exhibit anti-mitotic activity in cancer cells. Promising preclinical data have led to a single arm phase I/II trial in NSCLC patients...
  13. doi request reprint Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
    Richard Cathomas
    Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland
    Clin Cancer Res 18:6049-57. 2012
    ..The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not been tested in patients with prostate cancer...
  14. doi request reprint Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts
    Roger von Moos
    Medical Oncology, Kantonsspital Graubunden, Loestrasse 170, Chur 7000, Switzerland
    Eur J Cancer 44:781-90. 2008
    ..It can cause considerable discomfort and lead to therapy interruption. Numerous approaches to HFS management have been reported, but there is no consensus...
  15. doi request reprint Spontaneous pneumothorax during chemotherapy: a case report
    Martin Fehr
    Division of Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland
    Onkologie 33:527-30. 2010
    ..Spontaneous pneumothorax (SP) associated with malignant disease is relatively infrequent but has important diagnostic and therapeutic implications...
  16. doi request reprint Fatal herpes simplex virus hepatitis in a patient with esophageal cancer under radiochemotherapy
    Birgit Grimm
    Abteilung Onkologie Hamatologie, Departement Innere Medizin, Kantonsspital Graubunden, Chur, Switzerland
    Onkologie 31:620-2. 2008
    ..Herpes simplex virus (HSV) infections are frequent. However, HSV hepatitis is rare and may lead to a life-threatening condition...
  17. ncbi request reprint Bisphosphonate treatment recommendations for oncologists
    Roger von Moos
    Rätisches Kantons und Regionalspital, Loestrasse 170, CH 7000, Chur, Switzerland
    Oncologist 10:19-24. 2005
    ..Clinical studies also indicate that 50 mg oral ibandronate has an efficacy similar to that of i.v. bisphosphonates and is associated with a low incidence of adverse gastrointestinal events...
  18. ncbi request reprint Severe hyponatremia in a patient with mantle cell lymphoma treated with bortezomib: a case report and review of the literature
    Stefan Brodmann
    Abteilung Onkologie Hamatologie, Departement Innere Medizin, Kantonsspital Graubunden, Chur, Switzerland
    Onkologie 30:651-4. 2007
    ..We observed this side effect in a patient treated with bortezomib. This paper gives an overview of the literature on antineoplastic agents that have been associated with hyponatremia...